This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter.

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up ...

Also Read: Abbott Laboratories’ Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst. “Our results this quarter demonstrate the strength of our diversified ...

A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies ...

There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...